文献速递临床试验与 GCP基础与转化研究

INHALE试验:FilmArray肺炎面板分子诊断对英国重症监护中医院获得性和呼吸机相关性肺炎的抗微生物药物管理与患者结局的影响——多中心随机对照试验研究方案

INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care-study protocol for a multicentre randomised controlled trial.
PubMed 文献 · Trials · 2021-10-07

INHALE试验是一项多中心平行随机对照试验,旨在评估BioFire FilmArray分子诊断引导抗生素治疗HAP/VAP能否改善患者结局和抗微生物药物管理。研究纳入成人及儿科ICU疑似下呼吸道感染患者,1:1随机接受分子诊断引导治疗或标准治疗,共同主要结局为14天临床治愈的非劣效性和24小时抗微生物药物管理的优越性,计划样本量552例。

要点

  • FilmArray可在约90分钟内识别HAP/VAP病原体及关键耐药性,标准培养通常需48-72小时。
  • 共同主要结局:14天肺炎临床治愈的非劣效性;24小时抗微生物药物管理的优越性。
  • 计划样本量552例,以90%把握度和5%显著性水平检测共同主要结局。

核心结论

  • 该试验将检验HAP/VAP快速分子诊断的潜在优势能否转化为患者结局改善和/或抗微生物药物管理优化。

研究设计与样本

  • 多中心平行随机对照试验,纳入成人及儿科ICU疑似下呼吸道感染(含HAP/VAP)患者,1:1随机分组。
  • 样本量552例,以90%把握度和5%显著性水平检测共同主要结局。

关键数值与推荐

  • FilmArray分子诊断可在约90分钟内识别病原体和关键抗生素耐药性。
  • 对照组接受经验性抗生素直至微生物培养结果可用,通常需48-72小时。
  • 共同主要结局为随机化后14天肺炎临床治愈的非劣效性和随机化后24小时抗微生物药物管理的优越性(定义为使用活性且比例适当抗生素的患者百分比)。

临床怎么用

  • 疑似HAP/VAP的ICU患者需住院48小时或以上,首次接受抗生素或因临床恶化更换抗生素时可纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hospital-acquired and ventilator-associated pneumonias (HAP and VAP) are common in critical care and can be life-threatening. Rapid microbiological diagnostics, linked to an algorithm to translate their results into antibiotic choices, could simultaneously improve patient outcomes and antimicrobial stewardship. METHODS: The INHALE Randomised Controlled Trial is a multi-centre, parallel study exploring the potential of the BioFire FilmArray molecular diagnostic to guide antibiotic treatment of HAP/VAP in intensive care units (ICU); it identifies pathogens and key antibiotic resistance in around 90 min. The comparator is standard care whereby the patient receives empirical antibiotics until microbiological culture results become available, typically after 48-72 h. Adult and paediatric ICU patients are eligible if they are about to receive antibiotics for a suspected lower respiratory infection (including HAP/VAP) for the first time or a change in antibiotic because of a deteriorating clinical condition. Breathing spontaneously or intubated, they must have been hospitalised for 48 h or more. Patients are randomised 1:1 to receive either antibiotics guided by the FilmArray molecular diagnostic and its trial-based prescribing algorithm or standard care, meaning empirical antibiotics based on local policy, adapted subsequently based upon local microbiology culture results. Co-primary outcomes are (i) non-inferiority in clinical cure of pneumonia at 14 days post-randomisation and (ii) superiority in antimicrobial stewardship at 24 h post-randomisation (defined as % of patients on active and proportionate antibiotics). Secondary outcomes include further stewardship reviews; length of ICU stay; co-morbidity indicators, including septic shock, change in sequential organ failure assessment scores, and secondary pneumonias; ventilator-free days; adverse events over 21 days; all-cause mortality; and total antibiotic usage. Both cost-effectiveness of the molecular diagnostic-guided therapy and behavioural aspects determining antibiotic prescribing are being explored. A sample size of 552 will be required to detect clinically significant results with 90% power and 5% significance for the co-primary outcomes. DISCUSSION: This trial will test whether the potential merits of rapid molecular diagnostics for pathogen and resistance detection in HAP/VAP are realised in patient outcomes and/or improved antibiotic stewardship. TRIAL REGISTRATION: ISRCTN Registry ISRCTN16483855 . Retrospectively registered on 15 July 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. High J, Enne VI, Barber JA, et al. INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care-study protocol for a multicentre randomised controlled trial. Trials. 2021. PMID: 34620213. doi:10.1186/s13063-021-05618-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。